? DUKE IMMUNE PROFILING CORE SHARED RESOURCE The Duke Immune Profiling Core (DIPC) was a developing Shared Resource and is being submitted as a new Duke Cancer Institute ? CCSG Shared Resource. The overarching mission for the DCI is to impact the existing ?standard of medical care? with respect to cancer treatment by working to identify immunologic signatures that predict clinical outcomes. The DIPC shared resource is comprised of 2 components. The first is a Service component in which DIPC provides comprehensive, highly standardized, state-of-the-art human immunologic profiling services in support of both intra- and extra-mural translational research endeavors, including Phase I/II clinical trials. The second DIPC component focuses on Discovery, and utilizes advanced, high dimensional Core technologies and resources to stimulate innovative translational research initiatives that will impact the existing ?standard of medical care.? With over 28 years of experience in flow cytometry and immune profiling, we are available to support a wide range of studies from small-scale projects for generating pilot data through to clinical trial testing. Additionally, our services include study design, performance of experiments, data collection and analysis, and writing support. Moving forward, we will further enhance our data acquisition and analytical capacity in order to provide DCI members with innovative methods to evaluate patient specimens. In 2018, the DIPC shared resource, which has been in existence for 18 months, provided services to 36 investigators, 56% of whom were DCI members, accounting for 65% of total usage, from 7 of the 8 DCI Research Programs. Use of this Shared Resource by DCI members, contributed to 20 publications over the project period, 6 of which were in high impact journals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014236-46
Application #
9853591
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
46
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784
Dai, Ziwei; Mentch, Samantha J; Gao, Xia et al. (2018) Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun 9:1955
Powell Gray, Bethany; Kelly, Linsley; Ahrens, Douglas P et al. (2018) Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. Proc Natl Acad Sci U S A 115:4761-4766

Showing the most recent 10 out of 513 publications